Genetic engineering in humans has moved from theoretical promise to measurable clinical results, with benefits now spanning the treatment of fatal blood disorders, aggressive cancers, inherited blindness, and viral infections that were previously considered incurable. The most dramatic example arrived in 2023, when regulators approved the first CRISPR-based gene-editing therapy for sickle cell disease, but the broader landscape includes dozens of applications at various stages of development. The range of conditions that gene editing and gene therapy can address keeps expanding, and the results in many cases go beyond symptom management toward something closer to functional cures.
Curing Inherited Blood Disorders
Sickle cell disease and beta-thalassemia are caused by mutations in a single gene that controls hemoglobin, the oxygen-carrying molecule in red blood cells. For decades, the only cure was a bone marrow transplant from a matched donor, which most patients could not access. CRISPR-Cas9 gene editing has changed that picture dramatically. The treatment works by editing a patient’s own blood stem cells to reactivate fetal hemoglobin, a form of the protein that compensates for the defective adult version.
The earliest published results showed that two patients, one with transfusion-dependent thalassemia and one with sickle cell disease, achieved high levels of fetal hemoglobin after receiving edited cells. Both became transfusion-independent, and the sickle cell patient had no more pain crises more than a year after treatment.1PubMed. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia Larger trials have reinforced those findings. In a study of 44 patients with sickle cell disease, roughly 94% of those evaluated were free from severe pain crises for at least 12 consecutive months after a single treatment.2PubMed Central. CRISPR/Cas9 in the treatment of sickle cell disease (SCD) and its comparison with traditional treatment approaches: a review
Longer follow-up data now shows that the effects hold. In the combined final results from the pivotal trials, all evaluable patients maintained freedom from pain crises and elevated fetal hemoglobin, with normal or near-normal total hemoglobin levels persisting from six months onward. The average crisis-free period stretched past 35 months, and about 95% of red blood cells expressed fetal hemoglobin. Researchers have described these outcomes as evidence of a one-time functional cure.3Blood. Long-term follow-up demonstrates durable clinical benefits of exagamglogene autotemcel for sickle cell disease with recurrent vaso-occlusive crises: Final results of climb SCD-121
Restoring Sight and Movement
Gene therapy entered mainstream medicine when Luxturna, an AAV-based treatment for an inherited form of blindness, received FDA approval. Patients with mutations in the RPE65 gene experienced life-changing improvements in light sensitivity and the ability to navigate visually after treatment.4Molecular Therapy. Adeno-Associated Virus-Mediated Gene Therapy for Inherited Diseases This was not a marginal improvement in test scores on an eye chart; it meant people who had lived in near-total darkness could suddenly see well enough to move through a room without help.
Spinal muscular atrophy, a condition that progressively destroys motor neurons in infants, has been another dramatic success story. In a key trial, all 12 infants who received the therapeutic dose of a gene therapy delivering a functional copy of the missing SMN1 gene were alive and free of permanent ventilation at the study’s conclusion. Eleven could sit without assistance, nine could roll over, and two could walk independently. Motor function scores climbed rapidly, improving by about 15 points within just three months.5Molecular Therapy. Adeno-Associated Virus-Mediated Gene Therapy for Inherited Diseases – Section: Clinical Gene Therapy in Neuromuscular Disorders Without treatment, these children would typically lose the ability to swallow and breathe on their own within months.
Engineering Immune Cells to Fight Cancer
CAR-T cell therapy represents one of the most visible benefits of genetic engineering in medicine. The concept is straightforward, even if the execution is complex: take a patient’s own immune cells, genetically modify them to recognize and attack cancer cells, then infuse them back into the body. The approach has produced striking results in blood cancers, particularly B-cell leukemia and lymphoma, where patients who had exhausted all other options achieved complete remissions.6PubMed Central. CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments
CRISPR gene editing has pushed this further by allowing researchers to fine-tune T cells with greater precision. Edited T cells can be designed to have more accurate tumor recognition, lower side effects, stronger ability to multiply inside the body, and reduced exhaustion, a state where immune cells lose their potency over time.7PubMed Central. CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy One important advance involves using gene editing to knock out multiple genes at once, disabling the T cell’s own immune identity markers and a built-in brake called PD-1 simultaneously. This opens the door to “off-the-shelf” therapies made from donor cells rather than each individual patient’s own cells, which could slash costs and wait times.8PubMed Central. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
Researchers have taken this even further by simultaneously editing out the T-cell receptor, HLA class I, and HLA class II molecules, creating cells that are far more resistant to rejection by the patient’s own immune system. In animal models and lab testing, these triple-edited cells retained their ability to kill cancer cells while avoiding the host-versus-graft rejection that limits standard donor-derived therapies.9PubMed Central. Simultaneous editing of TCR, HLA-I/II and HLA-E resulted in enhanced universal CAR-T resistance to allo-rejection
Tackling Infectious Diseases at the Genetic Level
HIV has long been considered manageable but not curable. Antiretroviral drugs suppress the virus effectively, but they do not eliminate it from the body. Genetic engineering offers a different angle of attack. The virus enters human cells primarily through a receptor called CCR5, and a rare natural mutation that disables this receptor confers near-complete resistance to the most common strain of HIV. The so-called “Berlin Patient” and “London Patient” both carried this mutation and were functionally cured after receiving bone marrow transplants from donors with the same genetic variant.10PubMed Central. CCR5 gene editing and HIV immunotherapy: current understandings, challenges, and future directions
Researchers are now trying to replicate that natural protection artificially. Gene-editing tools have been used to disable CCR5 in a patient’s own T cells, which were then infused back. An early clinical trial using zinc-finger nucleases demonstrated that this approach is feasible and safe in people living with HIV.11PubMed Central. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV Meanwhile, CRISPR-based editing of the HIV genome itself has shown it can directly cleave and disrupt the virus’s genetic material in latently infected cells, potently inhibiting replication.12ACS Infectious Diseases. CRISPR/Cas9 and Genome Editing for Viral Disease Is Resistance Futile?
HIV is not the only virus in the crosshairs. Herpes simplex virus type 1 establishes a lifelong latent infection that periodically reactivates, and there is no cure. A CRISPR-Cas9 platform targeting key viral genes drastically suppressed HSV-1 replication in cell culture and, in a 3D brain organoid model mimicking latent infection, significantly reduced viral rebound after reactivation.13PubMed Central. Suppression of HSV-1 infection and viral reactivation by CRISPR-Cas9 gene editing in 2D and 3D culture models The prospect of actually eliminating a latent virus from the body, rather than merely suppressing symptoms, would represent a genuine paradigm shift.
Preventing Heart Disease With a Single Treatment
Heart disease kills more people worldwide than any other condition, and high LDL cholesterol is one of its biggest drivers. Most people manage cholesterol with daily statin pills, but genetic engineering may eventually offer a one-and-done alternative. A gene called PCSK9 controls how much LDL cholesterol the liver clears from the bloodstream. People born with naturally low-functioning PCSK9 have remarkably low cholesterol levels and very low rates of heart disease.
An in vivo base-editing therapy called VERVE-102 has been tested in patients with dangerously high cholesterol. The treatment uses lipid nanoparticles to deliver a base editor directly to liver cells, making a single-letter change in the PCSK9 gene. In a clinical trial, the highest dose cut PCSK9 protein levels by about 88% and LDL cholesterol by about 62%, with reductions appearing to hold for at least a year.14PubMed. In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia If these results hold in larger trials, a single infusion could replace decades of daily medication for millions of people at high cardiovascular risk.
Treating Diseases That Destroy Nerves and Organs
Transthyretin amyloidosis is a condition where a misfolded protein produced by the liver accumulates in the heart and nerves, progressively destroying them. The first-ever in vivo CRISPR therapy delivered directly into a person’s bloodstream targeted this disease. After a single infusion, patients receiving the higher dose saw the toxic protein drop by roughly 87% within a month.15PubMed. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis Follow-up data from an expanded cohort showed reductions exceeding 90% across all dose groups, sustained through at least four to six months.16PubMed Central. Lessons from the first-in-human in vivo CRISPR/Cas9 editing of the TTR gene by NTLA-2001 trial in patients with transthyretin amyloidosis with cardiomyopathy This was a landmark not just for the disease but for the entire field: it proved that CRISPR editing could be performed inside a living person’s body, not only in cells extracted and returned.
Editing Genes Before Birth
Some genetic diseases begin causing irreversible damage during fetal development. By the time a baby is born, organs may already be seriously compromised. In utero gene editing aims to intervene during the window when the fetus is small, the immune system is tolerant to introduced material, and stem cells across multiple organs are rapidly dividing and accessible.17PubMed Central. The Future of In Utero Gene Therapy
Animal studies have shown proof of concept in several devastating conditions. In a mouse model of a lethal lung disease caused by a surfactant protein mutation, precisely timed delivery of CRISPR into the amniotic fluid edited pulmonary cells, improved lung structure, and increased survival past birth.18PubMed Central. In utero gene editing for monogenic lung disease In cystic fibrosis, a disease that affects the lungs, gut, and reproductive system before birth, systemic in utero delivery of gene-editing nanoparticles corrected the faulty gene across multiple organ systems. Treated mice showed normal CFTR function in both respiratory and gastrointestinal tissues after birth, without detectable off-target mutations.19PubMed Central. Systemic in utero gene editing as a treatment for cystic fibrosis These remain animal studies with significant hurdles before human trials, but they demonstrate a path to preventing diseases that currently have no prenatal treatment.
Reversing Age-Related Muscle Loss
Muscle wasting, whether from aging, cancer, or muscular dystrophy, severely reduces quality of life and independence. A protein called myostatin acts as a natural brake on muscle growth, and disabling it leads to substantial increases in muscle mass. In aged mice, CRISPR-mediated disruption of the myostatin gene in skeletal muscle significantly increased both the weight and the size of treated muscles, with more and larger individual muscle fibers compared to untreated controls.20Cancer Gene Therapy. Improvement of muscular atrophy by AAV–SaCas9-mediated myostatin gene editing in aged mice A separate approach using antibodies against myostatin in a mouse model of oculopharyngeal muscular dystrophy increased muscle mass by up to 41% and boosted strength by about 18%, while also reducing muscle scarring.21PubMed Central. Inhibition of myostatin improves muscle atrophy in oculopharyngeal muscular dystrophy (OPMD)
Importantly, people who naturally carry loss-of-function mutations in myostatin appear healthy aside from having larger-than-normal muscles, which suggests that targeting this pathway in humans may carry an acceptable safety profile. Researchers have proposed that CRISPR-based myostatin disruption could eventually help patients suffering from muscle wasting caused by cancer, aging, or prolonged immobility.22Molecular Therapy. Prevention of Muscle Wasting by CRISPR/Cas9-mediated Disruption of Myostatin In Vivo
A Genetic Approach to Alzheimer’s Disease
Alzheimer’s disease is not caused by a single gene, but genetic risk factors play a large role. The APOE4 variant is the strongest known genetic risk factor for the common, late-onset form of the disease. Carrying two copies of APOE4 can increase Alzheimer’s risk roughly tenfold. The APOE3 variant, by contrast, is associated with much lower risk, and the two differ by just a single DNA letter.
Two recent studies have demonstrated that gene editing can convert the high-risk APOE4 variant into the protective APOE3 form. One group used prime editing delivered by AAV vectors and showed successful conversion both in liver tissue after intravenous delivery and in brain tissue after direct hippocampal injection.23PubMed. Prime Editing of Alzheimer’s Disease High-Risk APOE4 Allele by Brain-Directed Adeno-Associated Virus Vectors Another team used an optimized prime editor called PE7 and demonstrated that the correction reduced amyloid buildup, tau protein phosphorylation, and markers of neuronal death in Alzheimer’s mouse models. Treated mice also performed better on cognitive tests. The same editing strategy worked in human neurons derived from an Alzheimer’s patient’s own cells.24PubMed Central. Therapeutic Gene Editing of APOE4 in Sporadic Alzheimer’s Disease via Prime Editor 7 This work is still preclinical, but it represents a fundamentally new approach: rather than clearing amyloid plaques after they form, the idea is to correct the genetic vulnerability that allows them to accumulate in the first place.
Safer Editing Tools
Early CRISPR-Cas9 techniques worked by cutting both strands of DNA, which is effective but carries a risk of unintended insertions or deletions at the cut site. Newer tools have been developed to avoid this problem. Base editors can change one DNA letter to another without making a double-strand break at all. Prime editors go further, capable of making any of the twelve possible single-letter swaps as well as small insertions and deletions, all without cleaving the DNA backbone.25PubMed Central. CRISPR-Cas9 DNA Base-Editing and Prime-Editing These advances improve safety by decreasing the likelihood of unwanted genetic changes at the target site.26PubMed. Base Editing and Prime Editing: Potential Therapeutic Options for Rare and Common Diseases
Delivery methods have also improved. The cholesterol-editing therapy described earlier and the transthyretin treatment both use lipid nanoparticles, tiny fat-based capsules that ferry the editing machinery into target cells without using a virus. This “hit and run” approach means the editing components are active briefly and then degrade, reducing the window for off-target effects.27PubMed Central. Lipid nanoparticles: The game-changer in CRISPR-Cas9 genome editing Lipid nanoparticle delivery has even been tested in human skin, where a single application achieved editing rates between 5% and 12%, a range that researchers believe may be enough to offset the most severe symptoms of some skin diseases.28PubMed Central. Lipid Nanoparticle-Mediated Hit-and-Run Approaches Yield Efficient and Safe In Situ Gene Editing in Human Skin
Another frontier involves editing the epigenome rather than the genome itself. A modified version of Cas9 called “dead” Cas9, which has had its cutting ability disabled, can be paired with chemical tags that turn genes up or down without altering the underlying DNA sequence.29PubMed. CRISPR-based epigenome editing: mechanisms and applications This could prove useful for diseases where a gene needs to be dialed down rather than destroyed, or where permanent DNA changes are considered too risky.
Making Animal Organs Compatible With Humans
More than 100,000 people in the United States alone are waiting for organ transplants at any given time, and thousands die each year before a donor organ becomes available. Genetic engineering of pig organs is being developed as a potential solution to this shortage. Pigs are anatomically similar enough to humans that their hearts and kidneys can, in principle, function in a human body, but the immune system normally destroys transplanted pig tissue within minutes.
Researchers have created pigs with ten genetic modifications: four pig genes knocked out (including the ones that trigger immediate immune rejection) and six human genes added (to help the organ interact with the human immune system). Hearts and kidneys from these engineered pigs have been studied in preclinical models using brain-dead human recipients.30PubMed Central. Physiological basis for xenotransplantation from genetically modified pigs to humans While this remains experimental, the fact that genetically engineered pig organs can survive in a human-like environment at all represents a significant step toward ending the organ shortage.
Longevity Research and Aging
Aging is not typically thought of as a disease, but many of the mechanisms that drive it are becoming targets for genetic intervention. Telomeres, the protective caps on the ends of chromosomes, shorten as cells divide, and their erosion is associated with aging and age-related disease. In a widely cited mouse study, a single dose of gene therapy delivering the telomerase enzyme to one-year-old and two-year-old mice improved insulin sensitivity, bone density, neuromuscular coordination, and several molecular markers of aging. Median lifespan increased by 24% in the younger group and 13% in the older group, without any increase in cancer rates compared to untreated mice.31PubMed Central. Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer
The cancer concern has historically been the main worry with telomerase-based approaches, since many cancers hijack telomerase to become immortal. The finding that delivering telomerase to adult animals did not increase tumor rates was a meaningful safety signal, though it remains to be seen whether this translates to humans. Broader reviews of the field confirm that experimental telomere elongation through genetic or pharmacological means has shown potential for delaying tissue aging across multiple organisms.32Frontiers in Aging. Unlocking longevity: the role of telomeres and its targeting interventions
Adapting Human Biology for Space
Long-duration spaceflight exposes astronauts to cosmic radiation, bone loss, muscle atrophy, and immune suppression, all of which worsen the further and longer humans travel from Earth. Genetic engineering has been proposed as a way to prepare human biology for these extreme conditions. CRISPR-based modifications targeting genes associated with radiation resistance, bone density, muscle maintenance, and immune function are being explored as potential countermeasures.33PubMed Central. Exploring the role of CRISPR in advancing space biotechnology: challenges and solutions for human survival beyond earth Separately, researchers have outlined strategies that include upregulating the body’s own DNA repair pathways and potentially introducing engineered radioprotective genes from other organisms that tolerate extreme radiation far better than humans do.34PubMed Central. Vive la radiorésistance!: converging research in radiobiology and biogerontology to enhance human radioresistance for deep space exploration and colonization This is speculative territory, well beyond the clinical trials happening today, but it illustrates how wide the eventual scope of human genetic engineering could be. The same tools being developed to cure sickle cell disease on Earth may one day help keep astronauts healthy on the way to Mars.